Nu.Q^® Immunoassay enables fast and reproducible monitoring of EZH2 inhibitor performance

We have developed and validated the Nu.Q® H3K27Me3 immunoassay, an automated blood-based assay for quantifying circulating H3K27Me3-nucleosomes—key biomarkers of EZH2 and PRC2 inhibitor activity.

By normalizing results with our Nu.Q® H3.1 assay, we enable accurate, non-invasive monitoring of epigenetic drug efficacy in both cellular and animal models. This platform supports real-time assessment during preclinical and clinical development, offering a powerful tool for advancing targeted cancer therapies.